Diane C. Young - 12 Nov 2021 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP, Chief Medical Officer
Signature
/s/ Sam Martin, attorney-in-fact for Diane C. Young
Issuer symbol
CLDX
Transactions as of
12 Nov 2021
Net transactions value
-$149,781
Form type
4
Filing time
16 Nov 2021, 15:02:33 UTC
Previous filing
21 Jun 2021
Next filing
17 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $47,748 +4,600 +217% $10.38 6,715 12 Nov 2021 Direct
transaction CLDX Common Stock Sale $197,529 -4,600 -69% $42.94 2,115 12 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -4,600 -6.4% $0.000000 67,400 12 Nov 2021 Common Stock 4,600 $10.38 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6400 to $43.2000 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F2 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.